Last year, a study reported that diabetes patients using GLP-1 drugs could face a twofold higher risk of developing age-related macular degeneration
Humana is the latest health insurer to expand into the fast-growing and lucrative business of direct-to-patient specialty pharmacy as demand grows for popular GLP-1 weight loss drugs
Clinical trials show an average weight loss of around 21%
Contrary to our hypothesis, no significant difference was found between ASD and control subjects in either GSH or GABA levels in any brain region
medical conditions potentially affecting the primary outcome (e.g., diabetes, nonalcoholic fatty liver disease)
To view a copy of this licence, visit About this article Cite this article Sattar, A.A., Matin, A.A., Hadwan, M.H